General Hospital Psychiatry
2026
Gabrielle F. M. Lovell, Shreya Vasudeva, Diana Orsini et al.
Ketamine is a dissociative anesthetic with potential for treating mood, anxiety, and related disorders; however, concerns have emerged regarding hepatotoxicity in the context of chronic treatment. Systematic searches of PubMed, Scopus, and Ovid databases were conducted from inception to August 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, and case...
Frontiers in Psychiatry
2026
Hang Yu, Yuqiong Zhu, Jie Wang et al.
Esketamine has a significant and rapid antidepressant effect. Although studies have shown that Neuregulin 1 (NRG1) and it's signaling pathway are associated with depression, the possible regulatory relationship of esketamine on the NRG1-ErbB4 pathway is not yet clear. To induce depressive-like behavior in mice, a Chronic Social Defeat Stress (CSDS) model was established. Behavioral indicators...
Therapeutic Advances in Psychopharmacology
2026
Alessandro Cuomo, Roger S McIntyre, Despoina Koukouna et al.
1 citation
Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited. To describe long-term dosing patterns and clinical outcomes associated with intranasal esketamine in routine clinical practice. Single-center observational cohort study with descriptive analyses. We analyzed 45 patients with TRD treated with intranasal...
Frontiers in Psychiatry
2026
Haihua Tian, Zongfeng Zhang, Yan He et al.
1 citation
Treatment-resistant depression (TRD) is often accompanied by persistent suicidal ideation and poor response to conventional antidepressants. Intranasal esketamine, a non-selective NMDA receptor antagonist, provides rapid antidepressant and anti-suicidal effects; transient dissociation is common, whereas ataxia-like "drunken gait" is rarely described. A 19-year-old woman with recurrent...
Frontiers in Pharmacology
2026
Michaela Krivosova, Matteo Marcatili, Gessica Guerrera et al.
Esketamine, the S-enantiomer of ketamine, is a rapid-acting antidepressant approved for treatment-resistant depression (TRD) when used in combination with an oral antidepressant. Identifying reliable clinical or genetic predictors of treatment response remains a critical unmet need. This study aimed to evaluate the impact of selected clinical and genetic variables on esketamine response in a...
Chronic Stress
2026
Alexis M Klinner, David S Middlemas
Treatment-resistant juvenile depression is a globally prevalent issue, with a need for better pharmacotherapy. Typically, Selective Serotonin Reuptake Inhibitors are front line, but recently there is interest in examining using ketamine or esketamine adjunct in adolescents. In this study, a novel method is used to explore the adverse effects of sub-anesthetic doses of ketamine in a female...
Frontiers in Immunology
2026
Qing Feng, Zhen Yuan, Qi An et al.
1 citation
Depression is increasingly recognized as a multifactorial disorder in which immune dysregulation contributes substantially to disease initiation, progression, and treatment response. Among the immune mediators implicated, serum inflammatory cytokines-including IL-1β, IL-6, TNF-α, IFN-γ, and C-reactive protein-have emerged as key links between peripheral inflammation and central nervous system...
Frontiers in Pharmacology
2026
Yang Qu, Shujin Li, Li Tian et al.
This study systematically evaluated the safety profile of esketamine for treatment-resistant depression through a meta-analysis, focusing on dose-dependent adverse events and associated risk factors to inform precision dosing. PubMed, Embase, the Cochrane Library, the Mainland China Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI) and Wanfang databases...
Therapeutic Advances in Psychopharmacology
2026
Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek
Treatment-resistant depression (TRD) and bipolar depression (TRBD) are severe, heterogeneous mood disorders associated with substantial functional impairment, elevated suicide risk and persistent unmet treatment needs. While pharmacological and psychological interventions continue to advance, many patients experience delayed, partial or unsustained benefit, underscoring the need for therapies...
Therapeutic Advances in Psychopharmacology
2026
Yujuan Liu, Xiaorong Liu, Sebastian Olbrich et al.
Ketamine has emerged as a promising rapid-acting antidepressant for treatment-resistant depression (TRD), yet its mechanisms of action and reliable biomarkers of treatment response remain poorly understood. Recent evidence suggests that the aperiodic exponent (1/f slope) of electroencephalography (EEG) power spectra reflects cortical excitation-inhibition balance (EIB), offering a potential...
Frontiers in Psychiatry
2026
Gláucio Silva Camargos, Geraldo Magela De Faria Júnior, Marcelo Lourenço et al.
This longitudinal observational study evaluated changes in depressive symptoms associated with ritualistic ayahuasca use in patients diagnosed with depressive disorders, as well as depressive burden in individuals with anxiety and substance use disorders. The research was conducted with 280 adults treated at clinics in the northwestern region of the state of São Paulo, under the jurisdiction of...
Advances in experimental medicine and biology
2026
Alessandro Spiti, Daniela Caldirola, Giampaolo Perna
1 citation
Major depressive disorder (MDD) continues to pose a major therapeutic challenge due to its clinical heterogeneity. This chapter looks at the development of antidepressant treatments, starting with early interventions such as electroconvulsive therapy (ECT), monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Although these treatments targeted the monoaminergic system,...
Advances in experimental medicine and biology
2026
Berend Olivier, Jocelien D A Olivier
Major depressive disorder (MDD), including treatment-resistant depression (TRD), is a highly prevalent psychiatric disorder. MDD is associated with severe suffering, burden and large economical costs. Although various conventional antidepressant treatments are available, a large portion of depressed people does not or not adequately respond to the first-line treatments (mostly SSRIs and SNRIs)...
Frontiers in Psychiatry
2026
Sofia Abramsky-Sze, Elliot Marseille, Richard Matzopoulos et al.
correction
[This corrects the article DOI: 10.3389/fpsyt.2025.1508811.].
Rural mental health
2026
Brian Shiner, Vincent Dufort, Tayla Peltzman et al.
While tele-mental health has improved access to standard medication management and psychotherapy for rural Veterans, implementation of interventional psychiatry treatments will require in-person care, potentially leading to the exacerbation of rural-urban disparities in access to mental health care. We studied the availability of interventional psychiatry treatments, delivered clinically or in...
Medicinska istrazivanja
2026
Stefan Jerotić, Olga Čolović, Nađa Marić
Psychedelic-assisted psychotherapy (PAP) is emerging as a novel intervention for major psychiatric disorders, most notably major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). While psychotherapy is widely regarded as a core element of PAP its precise role remains poorly defined. This narrative review traces the development of PAP within contemporary Western psychiatry,...
Genetics and Molecular Research
2026
Mahvash Khan, Muhammad Omar Malik, Sara Sajjad et al.
Background: Major depressive disorder is a prevalent psychological condition that is characterized by sustained low mood, dysfunction and biological dysregulation. Depression can be treated with cognitive behavioral therapy, and newer studies indicate that psilocybin-based therapy may improve depressive symptoms when used under supervised psychological support. Oxytocin, a neuropeptide that...
Figshare
2026
Daniel Pustay, Vishal Patel, Krista Ulisse et al.
preprint
Treatment-resistant depression (TRD) remains a complex challenge, often requiring interventions beyond standard medications. This review explores factors that may predict positive response to electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and ketamine-based treatments to help guide clinical decision-making. A systematic review was conducted following PRISMA...
Open Science Framework
2026
Christina Chwyl, M. Kati Lear, Sunjeev K. Kamboj et al.
preprint
Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorder (SAD). One proposed mechanism of MDMA-assisted therapy (MDMA-AT) for SAD is the cultivation of self-compassion. Across five aims, we will characterize self-compassion experiences during MDMA-AT and evaluate its role as a potential mechanism of...
Open Science Framework
2026
Annemarie van der Meij, Sotiris Poyiadis, Andrea Cipriani et al.
preprint
This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depressive disorder (TRD). The project is nested within an existing network meta-analysis for TRD (NMA-TRD) project, which has already been fully specified and registered: • Muit et al., BMJ Open 2022 – protocol for a systematic review and network...